Elevated circulating tumor DNA fraction and tumor suppressor gene loss are associated with worse prognosis in patients with prostate cancer liver metastases. Elevated circulating tumor DNA (ctDNA ...

Metastatic means the cancer has spread from the prostate to other parts of the body, like the bones, liver, or lungs. This makes the disease harder to treat since it's no longer just in one place.

Metastatic castration-resistant prostate cancer (mCRPC) is diagnosed by blood tests, imaging scans, and biopsies. Find out ...

Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy ...

Patients with liver metastasis have a poor prognosis and liver metastasis have been associated with the emergence of neuroendocrine prostate cancer post androgen receptor (AR) pathway inhibitors ...

Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising ...

Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.

The treatment of metastatic castration-resistant prostate cancer (mCRPC ... as well as the bladder, rectum, liver, lungs, and possibly the brain. With mCRPC, androgen deprivation therapy (ADT ...